Unity Biotechnology (UBX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Market Cap: $3.4MPipeline: 8 drugsFounded: 2009Employees: 0-10 (wind-down phase)HQ: San Francisco, United States

Sector Ranking#369 in Small Molecule Drugs #42 in Regenerative Medicine

Overview

Unity Biotechnology was founded on groundbreaking academic research into cellular senescence as a root cause of age-related diseases. Its mission was to develop selective senolytic medicines, initially focusing on localized delivery for ophthalmologic conditions like diabetic macular edema and neurodegenerative diseases. Despite promising early-stage clinical data and raising significant capital, the company faced clinical setbacks, pivoted its strategy, and ultimately ceased operations in 2024, marking the end of a prominent early player in the longevity therapeutics field.

OphthalmologyNeurologyMusculoskeletal

Technology Platform

A platform for discovering and developing senolytic medicines, primarily focused on small molecule inhibitors of the pro-survival protein Bcl-xL to selectively induce apoptosis in senescent cells while sparing healthy cells.

Pipeline

8

8 drugs in pipeline

Drug	Indication	Stage
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 m...	Neovascular Age-related Macular Degeneration	Phase 2
UBX1325	Diabetic Macular Edema (DME)	Phase 2
Aflibercept + foselutoclax	Diabetic Macular Edema	Phase 2
UBX0101	Osteoarthritis, Knee	Phase 2
UBX0101	Knee Osteoarthritis	Phase 1

Funding History

3

Total raised:$352M

IPO$85MUndisclosedMay 3, 2018

Series B$151MVenrockJun 15, 2017

Series A$116MARCH Venture PartnersJun 15, 2016

Opportunities

The senolytic field targets the multi-billion dollar markets of age-related diseases like diabetic macular edema and wet AMD, where a therapy offering durable efficacy with fewer injections would be highly disruptive.

The broader, long-term opportunity extends to virtually all chronic diseases of aging, representing one of the largest potential addressable markets in medicine.

Risk Factors

The company faced extreme translational risk in pioneering an entirely new drug modality, culminating in the catastrophic failure of its lead asset in Phase 2b.

Additional risks included the inherent toxicity profile of its Bcl-xL target and a precarious financial position dependent on binary clinical trial outcomes.

Competitive Landscape

Unity competed in a rapidly evolving senolytic landscape with numerous biotech startups (e.g., Oisín, Cleara, Rubedo) pursuing diverse mechanisms, as well as large pharmaceutical companies exploring aging biology. Its clinical failure ceded the lead, leaving the field open and highly competitive, with no approved therapies yet.